Stock detail

Incyte (INCY) stock price, chart, and key data

View Incyte stock price, chart movement, and headline metrics on Woodstock's stock detail page.

INCY

Stock detail

Incyte

INCY · XNAS

-$2.01 (-1.74%) past day

$113.76

Overnight $112.75 (-0.89%)

XNAS24/5 tradingLast updated: Jul 25, 01:01 PM

Key metrics

Financials

Quarterly revenue, profitability, and balance-sheet snapshot

2.261.691.130.560.00
FY2025 Q2Reported Revenue: $1BExpected Revenue: $1BNet income: $405MReported EPS: 2.04Expected EPS: 1.57
FY2025 Q3Reported Revenue: $1BExpected Revenue: $1BNet income: $424MReported EPS: 2.11Expected EPS: 2.26
FY2025 Q4Reported Revenue: $2BExpected Revenue: $1BNet income: $299MReported EPS: 1.46Expected EPS: 1.80
FY2026 Q1Reported Revenue: $1BExpected Revenue: $1BNet income: $303MReported EPS: 1.47Expected EPS: 1.81
FY2026 Q2Expected Revenue: $1B
FY2026 Q3Expected Revenue: $1B
1.5B1.2B904.1M602.7M301.4M0
FY25 Q2Q3Q4FY26 Q1Q2Q3

Operating income & Operating cash flow

Quarterly revenue, profitability, and balance-sheet snapshot

559.4M447.5M335.6M223.8M111.9M0
FY2024 Q4Operating income: $267MOperating cash flow: $381M
FY2025 Q1Operating income: $217MOperating cash flow: $266M
FY2025 Q2Operating income: $312MOperating cash flow: $45M
FY2025 Q3Operating income: $432MOperating cash flow: $559M
FY2025 Q4Operating income: $385MOperating cash flow: $543M
FY2026 Q1Operating income: $325MOperating cash flow: $369M
FY24 Q4FY25 Q1Q2Q3Q4FY26 Q1

Total assets & Total liabilities

Quarterly revenue, profitability, and balance-sheet snapshot

7.3B5.9B4.4B2.9B1.5B0
FY2024 Q4Total assets: $5BTotal liabilities: $2B
FY2025 Q1Total assets: $6BTotal liabilities: $2B
FY2025 Q2Total assets: $6BTotal liabilities: $2B
FY2025 Q3Total assets: $6BTotal liabilities: $2B
FY2025 Q4Total assets: $7BTotal liabilities: $2B
FY2026 Q1Total assets: $7BTotal liabilities: $2B
FY24 Q4FY25 Q1Q2Q3Q4FY26 Q1

Total equity & Shares outstanding

Quarterly revenue, profitability, and balance-sheet snapshot

5.6B4.5B3.4B2.2B1.1B0
FY2024 Q4Total equity: $3BShares outstanding: 193.5M
FY2025 Q1Total equity: $4BShares outstanding: 193.6M
FY2025 Q2Total equity: $4BShares outstanding: 195.3M
FY2025 Q3Total equity: $5BShares outstanding: 196.3M
FY2025 Q4Total equity: $5BShares outstanding: 199M
FY2026 Q1Total equity: $6BShares outstanding: 199.8M
FY24 Q4FY25 Q1Q2Q3Q4FY26 Q1

Day range

$115.00 - $118.83

52-week range

$67.27 - $119.60

Close price

$116.69

Market cap

$23.3B

P/E ratio

16.07

Beta

0.76

Financials

FY2026 Q1

Operating income

$325M

Operating cash flow

$369M

EPS

1.47

Shares outstanding

199.8M

Total assets

$7B

Total equity

$6B

Total liabilities

$2B

About the company

Incyte Genomics Inc

Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia. Incyte Corporation currently develops and manufactures prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity.

Analyst rating summary

A current read on analyst sentiment from the insight feed.

Mean target

$117

Current price $117
Low$99.00High$140

11

Hold

/ 20

Recent calls

07/20/2026

Goldman Sachs

Salveen Richter

Hold · Price target $110

07/20/2026

William Blair

Matt Phipps

Hold

07/21/2026

H.C. Wainwright

Mitchell Kapoor

Buy · Price target $140

Ticker holders

Review politician disclosures and insider transactions in tabs.

Holder directory

Select a heading to reorder by name, activity date, buy/sell, or displayed value.

5/5

#1Ro Khanna

democrat · House · CA-17

spouse
  • Sell$1,000 / $8,000 / $15,000
  • Sell$1,000 / $8,000 / $15,000
  • Sell$1,000 / $8,000 / $15,000
  • Sell$1,000 / $8,000 / $15,000
  • Buy$1,000 / $8,000 / $15,000
  • Sell$1,000 / $8,000 / $15,000
$6,000/$48,000/$90,000

#2Ro Khanna

democrat · House · CA-17

child
  • Buy$1,000 / $8,000 / $15,000
  • Buy$1,000 / $8,000 / $15,000
$2,000/$16,000/$30,000

#3Rob Bresnahan

republican · House · PA-8

self
  • Sell$1,001 / $8,001 / $15,000
$1,001/$8,001/$15,000

#4Ro Khanna

democrat · House · CA-17

self
  • Buy$1,000 / $8,000 / $15,000
$1,000/$8,000/$15,000

#5Donald J Trump

republican · Executive

self
2026
70/8/131

Market action

A concise summary of the latest filing, transaction, or market-moving item.

Incyte Corp. reported an insider equity-compensation transaction for Tray Thomas, reflecting grants made on July 16, 2026 and disclosed on a Form 4 filed July 20, 2026. The filing describes an award of restricted stock units, or RSUs, tied to Incyte common stock. The RSUs will vest 25% per year over four years and may be settled only in shares of Incyte common stock on a one-for-one basis. Including the July 16, 2026 grant, Thomas is reported as having an aggregate of 13,070 shares of common stock issuable under previously reported RSUs that have not yet vested. The report also notes a July 16, 2026 stock option grant. Those options become exercisable in 37 installments: the first 25% vest after one year, and the remaining portion vests monthly over the following three years. The provided filing text does not specify the number of options granted, the exercise price, or the total beneficial ownership after the transactions. No open-market purchase or sale is described in the provided document text. Instead, the filing appears to report routine insider equity awards as part of compensation, involving RSUs and options with multi-year vesting schedules. The transaction codes, per-security share counts for the new grants, and prices are not included in the supplied excerpt. The filing was signed on Thomas’s behalf by Elizabeth Feeney as attorney-in-fact on July 20, 2026.

24/5 Trading

Act on the stock when the timing works for you.

With Woodstock, you can move from chart review to order placement in one flow. Trade eligible US stocks 24/5, even outside regular market hours.

*24-hour trading is available except during system maintenance. Some stocks are not eligible for extended-hours trading.

Download the app
24/5 trading chart preview

Sign Up

Scan the QR code to get started

Contact via LINE

Scan the QR code to get started

LINE QR Code